Pluristem CEO Zami Aberman Elected to Board of Directors of the Alliance for Regenerative Medicine Print E-mail
Wednesday, 07 October 2015 18:24
HAIFA, Israel, Oct. 07, 2015 (GLOBE NEWSWIRE) -- Pluristem Therapeutics Inc. (PSTI) (PSTI), a leading developer of placenta-based cell therapy products, today announced that Pluristem’s Chairman and CEO, Zami Aberman, has been elected to serve on the Board of Directors of the Alliance for Regenerative Medicine (ARM). Based in Washington, D.C., ARM promotes research, development, investment and commercialization of regenerative medicine technologies. Pluristem has been a member of ARM for 3 years and has actively supported the organization’s goals. Mr. Aberman joins other prominent leaders in the field of regenerative medicine who are currently serving on the board.      Dr. Karine Kleinhaus, Divisional Vice President, North America, will present at 10:45 a.m. on October 7 at the Stem Cell Meeting on the Mesa to be held October 7-9, 2015 in La Jolla, California. Co-hosted by ARM, the California Institute for Regenerative Medicine (CIRM) and the Sanford Consortium for Regenerative Medicine, the 2015 Stem Cell Meeting on the Mesa is attended by leading cell therapy, gene therapy and tissue engineering companies, large pharma and biotech, industry investors and
major academic research institutions. A live video webcast of the presentation will be available at:http://stemcellmeetingonthemesa.com/webcast/ and will also be published on ARM’s website shortly after the event.     About Pluristem Therapeutics Pluristem Therapeutics Inc. is a leading developer of placenta-based cell therapy products. The Company has reported robust clinical trial data in multiple indications for its patented PLX (PLacental eXpanded) cells. The cells release a cocktail of therapeutic proteins in response to inflammation, ischemia, hematological disorders, and radiation damage. PLX cell products are grown using the Company's proprietary three-dimensional expansion technology. They are off-the-shelf, requiring no tissue matching prior to administration. Pluristem has a strong intellectual property position; Company-owned, GMP-certified manufacturing and

Error. Page cannot be displayed. Please contact your service provider for more details. (24)

research facilities; strategic relationships with major research institutions; and a seasoned management team.
 
University of Michigan Selects Tactio Remote Patient Monitoring Platform to Support Clinical Pharmacist Management of Patients With Uncontrolled Hypertension Print E-mail
Monday, 05 October 2015 14:18
SANTA CLARA, Calif. --Tactio Health Group has been selected by the University of Michigan Department of Family Medicine to provide its TactioRPM Remote Patient Monitoring Platform in a pilot study that will implement a mobile pharmacist-led home blood pressure (BP) monitoring program.
Read more...
 
Pluristem Completed Successful Meeting With the U.S. FDA in Preparation for Filing an IND for PLX-R18 to Treat Incomplete Hematopoietic Recovery After Bone Marrow Transplantation Print E-mail
Wednesday, 09 September 2015 12:57
HAIFA, Israel--Pluristem Therapeutics Inc. (Nasdaq:PSTI) (TASE:PSTI), a leading developer of placenta-based cell therapy products, today announced that it has completed a successful meeting with the U.S. Food and Drug Administration (FDA) regarding the initiation of a Phase I clinical trial for its PLX-R18 cells in the treatment of incomplete hematopoietic recovery following hematopoietic cell transplantation.
Read more...
 
Oramed Completes Randomization of Over 50% of Patients in Phase IIb Oral Insulin Study Print E-mail
Wednesday, 09 September 2015 12:21
JERUSALEM September 9, 2015 — Oramed Pharmaceuticals Inc. (NASDAQ: ORMP) (www.oramed.com), a clinical-stage pharmaceutical company focused on the development of oral drug delivery systems, announced today that 98 patients have already been enrolled in the Company’s Phase IIb study of its oral insulin capsule, ORMD-0801, which represents more than 50% of the 180 patients expected to be recruited for the trial.
Read more...
 
CEL-SCI Reports August Patient Enrollment for Its Phase 3 Head and Neck Cancer Trial Print E-mail
Wednesday, 02 September 2015 11:13
Vienna, VA, September 1, 2015 --CEL-SCI Corporation (NYSE MKT: CVM) today announced that in the month of August it has enrolled 19 patients in its ongoing Phase 3 trial of its investigational immunotherapy Multikine* (Leukocyte Interleukin, Injection) in patients with advanced primary squamous cell carcinoma of the oral cavity/soft palate, a type of head and neck cancer.
Read more...
 
Medicortex Developing New Biomarker Diagnostic Tools to Gauge Severity and Extent of Traumatic Brain Injuries and Strokes Print E-mail
Wednesday, 26 August 2015 11:16
TURKU, FINLAND / ACCESSWIRE / August 26, 2015 / Medicortex Finland Oy has established a new diagnostic division/arm to its core business with the goal of developing a biomarker diagnostic test that would reliably establish the severity and extent of brain injuries.
Read more...
 
Key Executive with Significant Hematology Drug Development Expertise Joins Actinium Pharmaceuticals as Head of Clinical Development Print E-mail
Tuesday, 18 August 2015 17:03
NEW YORK, NY – August 18, 2015 – Actinium Pharmaceuticals, Inc. (NYSE MKT: ATNM) ("Actinium" or "the Company"), a biopharmaceutical Company developing innovative targeted payload immunotherapeutics for the treatment of advanced cancers, announced today the appointment of Felix Garzon, MD, Ph.D. to the position of Senior Vice President, Head of Clinical Development effective August 17, 2015.  
Read more...
 
Pluristem Granted U.S. Patent for Production Methods and Use of Placental Cell Therapy in a Range of Indications Print E-mail
Monday, 17 August 2015 13:25
HAIFA, Israel, Aug. 17, 2015 (GLOBE NEWSWIRE) -- Pluristem Therapeutics Inc. (Nasdaq:PSTI) (TASE:PSTI), a leading developer of placenta-based cell therapy products, today announced that the U.S. Patent and Trademark Office has issued to the Company patent #9,096,827 titled "Adherent Cells From Placenta Tissue and Use Thereof in Therapy".
Read more...
 
Pluristem in Key Discussions with Europe's Adaptive Pathways Group on Phase II Protocol in Critical Limb Ischemia Print E-mail
Monday, 10 August 2015 21:06
HAIFA, Israel--Pluristem Therapeutics Inc. (Nasdaq:PSTI) (TASE:PSTI), a leading developer of placenta-based cell therapy products, today announced that it has conducted detailed discussions with the European Adaptive Pathways Discussion Group regarding the clinical development plan for PLX cells in Critical Limb Ischemia (CLI) patients, and received guidance on the planned design of the initial Phase II trial of PLX cells in a subgroup of patients with severe CLI.
Read more...
 
New Data Show Pluristem’s PLX Cells Regulate the Immune System Print E-mail
Monday, 27 July 2015 11:25
HAIFA, ISRAEL, July 27, 2015 --Pluristem Therapeutics Inc. (NasdaqCM: PSTI , TASE: PLTR),a leading developer of placenta-based cell therapy products, today announced the publication of a scientific study regarding PLacental eXpanded (PLX) cells in the prominent peer-reviewed journal Stem Cells.
Read more...
 
<< Start < Prev 1 2 3 4 5 6 7 8 9 10 Next > End >>

Page 1 of 12
BMR:1